[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562611":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":10,"centralContacts":39,"locations":48,"responsibleParty":79,"collaborators":81,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":109,"sex":115,"minAge":10,"maxAge":10,"enrollmentInfo":116,"targetDuration":10,"studyType":119,"phases":10,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"L\u002FGCMN",null,"Patients with congenital nevus with estimated size of 20 cm or more in adulthood (\\> 18 years old)",[13,14,15,16],"Genetic: Methylomics","Genetic: RNA sequencing","Genetic: Spatial transcriptomics","Genetic: Liquid biopsy",{"label":18,"type":10,"description":19,"interventionNames":20},"Melanoma","Patients affected with Spitz-type or conventional melanomas in patients under 30 years of age",[13,14,15,16],[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"GENETIC","Methylomics","Methylomics analysis of FFPE blocks and frozen tissues",[9,18],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"RNA sequencing","RNA sequencing of FFPE blocks and frozen tissues",[9,18],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Spatial transcriptomics","Spatial transcriptomics of FFPE blocks and frozen tissues",[9,18],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"Liquid biopsy","cfDNA characterization extracted from blood\u002Fsaliva",[9,18],[40,45],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Susana Puig Sardà, MD, PhD","CONTACT","+34932275400","spuig@clinic.cat",{"name":46,"role":42,"phone":10,"phoneExt":10,"email":47},"Adrián López Canosa, PhD","lopez64@recerca.clinic.cat",[49,66],{"facility":50,"status":51,"city":52,"state":10,"zip":10,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"French National Institute of Health and Medical Research","RECRUITING","Marseille","France","FR",{"type":56,"coordinates":57},"Point",[58,59],5.38107,43.29695,{"lat":59,"lon":58},[62],{"name":63,"role":42,"phone":64,"phoneExt":10,"email":65},"Heather Etchevers, PhD","+33491324937","heather.etchevers@inserm.fr",{"facility":67,"status":51,"city":68,"state":10,"zip":10,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Hospital Clínic de Barcelona (Dermatology service)","Barcelona","Spain","ES",{"type":56,"coordinates":72},[73,74],2.15899,41.38879,{"lat":74,"lon":73},[77],{"name":78,"role":42,"phone":43,"phoneExt":10,"email":44},"Susana Puig Sardà, PhD, MD",{"type":80,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[82,85,87,89,91,93,95,97,99,101,103,105],{"name":83,"class":84},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"name":86,"class":6},"University Hospital Tuebingen",{"name":88,"class":6},"University of Florence",{"name":90,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"name":92,"class":6},"University Of Perugia",{"name":94,"class":6},"German Cancer Research Center",{"name":96,"class":6},"Karolinska Institutet",{"name":98,"class":6},"Maria Sklodowska-Curie National Research Institute of Oncology",{"name":100,"class":6},"Institut Curie",{"name":102,"class":6},"Medical University of Gdansk",{"name":104,"class":6},"Princess Maxima Center for Pediatric Oncology",{"name":106,"class":6},"Institut Català d'Oncologia","100562611","understanding-the-transition-from-normal-melanocytes-to-nevus-to-melanoma-100562611",false,"NCT06605417","Understanding the Transition from Normal Melanocytes to Nevus to Melanoma","Understanding the Transition from Normal Melanocytes to Nevus to Melanoma (NevustoMel)","NevustoMel","Inclusion criteria:\n\n* Congenital nevus with estimated size of 20 cm\n* Be over 18 years of age\n\nExclusion criteria:\n\n* No available biological material\n* Not having signed the informed consent","ALL",{"count":117,"type":118},100,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L\u002FGCMN. The secondary objectives are:\n\n* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients.\n* To improve the early diagnosis and treatments for intermediate conditions such as L\u002FGCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources.\n* To test pre-clinical strategies to best model and improve patient response.",[122,123,124],"Congenital Melanocytic Nevi","Melanoma, Skin","Nevi and Melanomas",[126,18,36,127,24,9,128,129],"Congenital melanocytic nevi","cfDNA","RNAseq","Molecular profiles","2025-02-25",{"date":132,"type":133},"2025-02-27","ACTUAL",{"date":135,"type":133},"2024-01-01",{"date":137,"type":118},"2026-11-30",{"name":5,"class":6},2]